Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer

被引:14
作者
He, Yu-Wen [1 ]
Zhao, Mei-Ling [2 ]
Yang, Xin-Yun [1 ]
Zeng, Jun [3 ]
Deng, Qiu-Hua [1 ]
He, Jian-Xing [2 ]
机构
[1] Guangzhou Med Univ, Dept Pharm, Affiliated Hosp 1, Guangzhou 510120, Guangdong, Peoples R China
[2] Guangzhou Med Univ, State Key Lab Resp Dis, Affiliated Hosp 1, Dept Thorac Surg, Guangzhou 510120, Guangdong, Peoples R China
[3] Guangzhou Med Univ, Dept Med Genet & Cell Biol, Guangzhou 510120, Guangdong, Peoples R China
关键词
Non-small cell lung cancer; Excision repair cross-complementation group 1; Ribonucleotide reductase M1; Thymidylate synthase; Chemotherapy; THYMIDYLATE SYNTHASE; DNA-REPAIR; PREDICTIVE BIOMARKERS; EXPRESSION; SURVIVAL; REDUCTASE; CHEMOTHERAPY; EXCISION; MARKERS;
D O I
10.1007/s00280-015-2714-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent clinical trials showed that expression of excision repair cross-complementation group 1 (ERCC1), ribonucleotide reductase M1 (RRM1), and thymidylate synthase (TS) proteins was able to predict the effects of non-small cell lung cancer (NSCLC) to chemotherapy. However, it remains unknown whether the adjuvant chemotherapy based on expression of the three proteins has survival significance in Chinese NSCLC patients. We investigated 128 Chinese patients receiving chemotherapy after tumor resection for expression of these proteins using immunohistochemistry. Based on protein expression, patients were assigned to two groups for different adjuvant chemotherapy regimes. The disease-free survival (DFS) data were collected and analyzed using Kaplan-Meier curves and Cox models. We found that DFS of these patients with carboplatin and a third-generation agent (gemcitabine or pemetrexed) stratified by protein expression showed no statistical difference between individual treatment versus non-individuation treatment analyzed using Kaplan-Meier method (P = 0.143, median 23.9 vs. 30.8 months). Furthermore, the multivariate analysis showed that histology and tumor stages were independent predictors for DFS in these patients. The results suggest that chemotherapy based on ERCC1, RRM1, and TS expression did not have significant impact on DFS of patients with resection of NSCLC.
引用
收藏
页码:861 / 867
页数:7
相关论文
共 38 条
  • [1] [Anonymous], 2020, CA Cancer J Clin, DOI DOI 10.3322/CAAC.21590
  • [2] Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer
    Arriagada, Rodrigo
    Dunant, Ariane
    Pignon, Jean-Pierre
    Bergman, Bengt
    Chabowski, Mariusz
    Grunenwald, Dominique
    Kozlowski, Miroslaw
    Le Pechoux, Cecile
    Pirker, Robert
    Pinel, Maria-Izabel Sathler
    Tarayre, Michele
    Le Chevalier, Thierry
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 35 - 42
  • [3] Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy
    Azuma, Koichi
    Komohara, Yoshihiro
    Sasada, Tetsuro
    Terazaki, Yasuhiro
    Ikeda, Jiro
    Hoshino, Tomoaki
    Itoh, Kyogo
    Yamada, Akira
    Aizawa, Hisamichi
    [J]. CANCER SCIENCE, 2007, 98 (09) : 1336 - 1343
  • [4] Randomized International Phase III Trial of ERCC1 and RRM1 Expression-Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non-Small-Cell Lung Cancer
    Bepler, Gerold
    Williams, Charles
    Schell, Michael J.
    Chen, Wei
    Zheng, Zhong
    Simon, George
    Gadgeel, Shirish
    Zhao, Xiuhua
    Schreiber, Fred
    Brahmer, Julie
    Chiappori, Alberto
    Tanvetyanon, Tawee
    Pinder-Schenck, Mary
    Gray, Jhanelle
    Haura, Eric
    Antonia, Scott
    Fischer, Juergen R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (19) : 2404 - +
  • [5] Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy
    Bergot, Emmanuel
    Levallet, Guenaelle
    Campbell, Karine
    Dubois, Fatemeh
    Lechapt, Emmanuele
    Zalcman, Gerard
    [J]. EUROPEAN RESPIRATORY REVIEW, 2013, 22 (130) : 565 - 576
  • [6] ERCC1 and RRM1: Ready for Prime Time?
    Besse, Benjamin
    Olaussen, Ken A.
    Soria, Jean-Charles
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (08) : 1050 - 1060
  • [7] ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy
    De Dosso, Sara
    Zanellato, Elena
    Nucifora, Martina
    Boldorini, Renzo
    Sonzogni, Angelica
    Biffi, Roberto
    Fazio, Nicola
    Bucci, Eraldo
    Beretta, Ottavio
    Crippa, Stefano
    Saletti, Piercarlo
    Frattini, Milo
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (01) : 159 - 165
  • [8] Predictive markers in the adjuvant therapy of non-small cell lung cancer
    Filipits, Martin
    Pirker, Robert
    [J]. LUNG CANCER, 2011, 74 (03) : 355 - 363
  • [9] ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform
    Friboulet, Luc
    Postel-Vinay, Sophie
    Sourisseau, Tony
    Adam, Julien
    Stoclin, Annabelle
    Ponsonnailles, Florence
    Dorvault, Nicolas
    Commo, Frederic
    Saulnier, Patrick
    Salome-Desmoulez, Sophie
    Pottier, Geraldine
    Andre, Fabrice
    Kroemer, Guido
    Soria, Jean-Charles
    Olaussen, Ken Andre
    [J]. CELL CYCLE, 2013, 12 (20) : 3298 - 3306
  • [10] ERCC1 Isoform Expression and DNA Repair in Non-Small-Cell Lung Cancer
    Friboulet, Luc
    Olaussen, Ken Andre
    Pignon, Jean-Pierre
    Shepherd, Frances A.
    Tsao, Ming-Sound
    Graziano, Stephen
    Kratzke, Robert
    Douillard, Jean-Yves
    Seymour, Lesley
    Pirker, Robert
    Filipits, Martin
    Andre, Fabrice
    Solary, Eric
    Ponsonnailles, Florence
    Robin, Angelique
    Stoclin, Annabelle
    Dorvault, Nicolas
    Commo, Frederic
    Adam, Julien
    Vanhecke, Elsa
    Saulnier, Patrick
    Thomale, Juergen
    Le Chevalier, Thierry
    Dunant, Ariane
    Rousseau, Vanessa
    Le Teuff, Gwenael
    Brambilla, Elisabeth
    Soria, Jean-Charles
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (12) : 1101 - 1110